Advertisement
Screener

PHATHOM PHARMACEUTICALS, INC. (PHAT) Analyst Insights

RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$5.23(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$5.23High(m)Average(m)Low(m)2025-11-062026-11-06
DateStockAnalystFirmPrice When RatedPrice TargetUpside / DownsideRatingPerformance
2026-08-14PHAT
Phathom Pharmaceuticals, Inc.
Jenna DavidnerBarclays$9.18$14.00+52.51%Overweight
2026-08-14PHAT
Phathom Pharmaceuticals, Inc.
Glen SantangeloBarclays$9.18$14.00+52.51%Overweight
2026-03-27PHAT
Phathom Pharmaceuticals, Inc.
Jenna DavidnerBarclays$10.47$18.00+71.92%Overweight
2026-03-27PHAT
Phathom Pharmaceuticals, Inc.
Glen SantangeloBarclays$10.47$18.00+71.92%Overweight
2025-12-08PHAT
Phathom Pharmaceuticals, Inc.
Jenna DavidnerBarclays$14.70$16.00+8.84%Equal Weight
2025-12-08PHAT
Phathom Pharmaceuticals, Inc.
Glen SantangeloBarclays$14.70$16.00+8.84%Equal Weight

Similar stocks

Stock NameCountryMarket CapPE Ratio
Altimmune, Inc. (ALT)United States$0.593B-6.43
Monopar Therapeutics (MNPR)United States$0.598B-34.82
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Evolus, Inc. (EOLS)United States$0.519B-13.32
Neurogene Inc. (NGNE)$0.625B-4.46